In adults hospitalized with COVID-19, adding baricitinib vs. dexamethasone to remdesivir did not differ for MV-free survival.
Ann Intern Med
; 175(10): JC115, 2022 10.
Article
in English
| MEDLINE | ID: covidwho-2110760
ABSTRACT
SOURCE CITATION Wolfe CR, Tomashek KM, Patterson TF, et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4) a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022;10888-99. 35617986.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Drug Treatment
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Limits:
Adult
/
Humans
Language:
English
Journal:
Ann Intern Med
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS